PCSK9 and hemorrhagic stroke: Similar to our study, FOURIER‐OLE (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated‐Risk–Open Label Extension) demonstrated that the frequency of AEs such as hemorrhagic stroke did not increase over >8 years of follow‐up among patients on evolocumab and did not exceed the rates observed in the placebo arm during the parent study.26